Skip to main content

Main menu

  • Home
  • Content
    • Published Ahead of Print
    • Current Issue
    • Podcasts
    • Subject Collections
    • Archives
    • ASN Meeting Abstracts
    • Saved Searches
  • Authors
    • Submit a Manuscript
    • Author Resources
    • Reprint Information
  • Trainees
    • Peer Review Program
    • Prize Competition
  • About CJASN
    • About CJASN
    • Editorial Team
    • CJASN Impact
    • CJASN Recognitions
  • More
    • Alerts
    • Advertising
    • Reprint Information
    • Subscriptions
    • Feedback
  • ASN Kidney News
  • Other
    • JASN
    • Kidney360
    • Kidney News Online
    • American Society of Nephrology

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
American Society of Nephrology
  • Other
    • JASN
    • Kidney360
    • Kidney News Online
    • American Society of Nephrology
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Advertisement
American Society of Nephrology

Advanced Search

  • Home
  • Content
    • Published Ahead of Print
    • Current Issue
    • Podcasts
    • Subject Collections
    • Archives
    • ASN Meeting Abstracts
    • Saved Searches
  • Authors
    • Submit a Manuscript
    • Author Resources
    • Reprint Information
  • Trainees
    • Peer Review Program
    • Prize Competition
  • About CJASN
    • About CJASN
    • Editorial Team
    • CJASN Impact
    • CJASN Recognitions
  • More
    • Alerts
    • Advertising
    • Reprint Information
    • Subscriptions
    • Feedback
  • ASN Kidney News
  • Visit ASN on Facebook
  • Follow CJASN on Twitter
  • CJASN RSS
  • Community Forum
Editorials
You have accessRestricted Access

Vancomycin and the Risk of AKI: Now Clearer than Mississippi Mud

Thomas D. Nolin
CJASN December 2016, 11 (12) 2101-2103; DOI: https://doi.org/10.2215/CJN.11011016
Thomas D. Nolin
*Center for Clinical Pharmaceutical Sciences, and Department of Pharmacy and Therapeutics, School of Pharmacy, and
†Renal-Electrolyte Division, Department of Medicine, School of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data Supps
  • Info & Metrics
  • View PDF
Loading
  • vancomycin
  • acute renal failure
  • nephrotoxicity
  • drug nephrotoxicity
  • Acute Kidney Injury
  • Mississippi
  • Risk
  • Vancomycin

Drug selection and dosing should be carried out with a firm understanding of the risk–benefit profile in individual patients in order to ensure a maximal likelihood of safety during treatment. Unfortunately, all drugs possess inherent risks. Unintended adverse effects not only tip the risk–benefit profile in an unfavorable direction, but often have major consequences, leading to increased morbidity, hospital admissions, length of stay, mortality, and health care costs (1). Drug-associated AKI is no exception. Medications have been implicated in up to 20% of hospital admissions because of AKI (2) and in 26% of all cases of in-hospital AKI (3), and the financial implications are enormous (4,5). Clearly, a better understanding of individual drug- and patient-related risk factors would enable clinicians to optimize treatment efficacy and safety when use of drugs with known toxicity is unavoidable.

The glycopeptide antibiotic vancomycin is the mainstay of therapy for infections because of methicillin-resistant Staphylococcus aureus. The drug was discovered >60 years ago by Eli Lilly scientists, who were in search of new antibacterial agents with activity against staphylococci because of the growing threat of penicillin-resistant organisms (6). Vancomycin, nicknamed “Mississippi mud” because early preparations were impure and brown in color, exhibited exceptional bactericidal activity against Gram-positive organisms, including penicillin-resistant staphylococci in vitro and in humans. Given the lack of effective therapeutic alternatives, this prompted the US Food and Drug Administration to quickly approve vancomycin in 1958, only 6 years after its discovery. Because of concerns with early reports of ototoxicity and nephrotoxicity, along with nearly simultaneous approval of methicillin, enthusiasm for vancomycin waned. It was infrequently prescribed, considered by most to be a niche drug restricted for use in patients with β-lactam allergies or infected with drug-resistant organisms (6). However, the emergence of methicillin-resistant S. aureus in the late 1970s, along with the development of newer formulations with improved purity, stimulated a >100-fold increase in the use of vancomycin over the subsequent 20 years (6,7). As depicted in Figure 1, this has been mirrored by a staggering rise in the number of vancomycin-related articles published annually since 1980. Although the number of published articles related specifically to “vancomycin nephrotoxicity” has also risen sharply (Figure 1), our understanding of the attributable risk of AKI because of vancomycin therapy has been as clear as Mississippi mud. In this issue of the Clinical Journal of the American Society of Nephrology, Ray et al. (8) report that intravenous vancomycin treatment is associated with a legitimate, albeit modest, increased risk of kidney injury.

Figure 1.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 1.

The number of reports with “vancomycin” in the title (left y-axis), and the number of reports of “vancomycin nephrotoxicity” (right y-axis) indexed in PubMed and published annually from 1980 to 2014 (19).

Currently, most agree that use of vancomycin monotherapy at conventional doses (e.g., 15 mg/kg every 12 hours) is safe and that nephrotoxicity is uncommon. Early studies reported incidence rates of 5%–20% (9,10), but even these numbers may be inflated by inconsistent use of criteria for assessing toxicity, AKI definitions, lack of control groups, and inadequate control of factors that may independently increase risk of AKI (e.g., procedures and patient comorbidities, particularly preexisting CKD). The current meta-analysis by Ray et al. addresses these issues, and in so doing provides clarity to our understanding of the risk of vancomycin-associated AKI. Importantly, the analysis included only cohort studies and randomized clinical trials that compared vancomycin to a non-nephrotoxic antibiotic, and this likely minimized bias because of confounding by indication. The authors report that parenteral vancomycin treatment is associated with a relative risk (RR) of AKI of 2.45 (95% confidence interval [95% CI], 1.69 to 3.55) and a corresponding attributable risk percentage of 0.59 (8). Although the RR of 2.45 may appear low in comparison to other known nephrotoxins, such as aminoglycosides (RR of up to ten) (11), the findings likely represent a conservative estimate and must be translated accordingly.

The meta-analysis has important implications that reflect its limitations. Perhaps most importantly, the study primarily included patients who received conventional vancomycin dosing and may not lend insight into the potential nephrotoxicity associated with more aggressive dosing and increased systemic exposure commonly observed in contemporary clinical practice. This topic has received considerable attention since the 2009 Infectious Diseases Society of America–endorsed clinical practice guidelines recommended maintaining trough vancomycin concentrations >10 mg/ml to avoid the development of resistance, and from 15 to 20 mg/ml in complicated infections caused by S. aureus infections to achieve the targeted area under the concentration-time curve-to-minimum inhibitory concentration ratio of ≥400 (12). Several studies strongly suggest that the higher recommended vancomycin trough concentrations and corresponding systemic exposure (13–15), or the larger doses required to achieve them (16), result in an increased risk of kidney injury. For instance, van Hal et al. (14) reported that troughs >15 mg/L were associated with increased odds of nephrotoxicity (odds ratio [OR], 2.67; 95% CI, 1.95 to 3.65) compared with troughs <15 mg/L. Similarly, Hanrahan et al. (15) reported that risk of vancomycin-associated AKI in critically ill patients increased as serum concentrations increased, with RR increasing from 1.07 to 1.53 and 2.21 (no 95% CI provided) in patients with trough concentrations of 15, 25, and >30 mg/L. These data support the notion that the RR of AKI of 2.45 observed in the setting of conventional dosing is likely to be much higher using contemporary dosing strategies, possibly because of the resulting increase in serum concentrations.

Another important limitation to bear in mind when considering the reported RR of 2.45 is that the analysis by Ray et al. primarily included studies that compared risk of AKI with vancomycin to the non-nephrotoxic antibiotic linezolid. It is well known that patients receiving concomitant nephrotoxic medications are more likely to develop vancomycin nephrotoxicity than patients who do not receive nephrotoxins (9,14). Recently, the risk of nephrotoxicity was shown to double in the setting of concomitant vancomycin and piperacillin-tazobactam therapy, rising from 8.1% in patients treated with vancomycin to 16.3% in those treated with both drugs (OR of 2.48 for the development of nephrotoxicity; one-sided chi-squared test, P=0.03; 95% CI>1.11) (17). Even more alarming is the risk of developing AKI with simultaneous use of vancomycin and aminoglycosides (OR, 18.9; 95% CI, 2.98 to 119.81) (18). Clearly, kidney toxicity profiles of individual drugs may change when used in combination with other medications, and heightened awareness is warranted in this situation.

In summary, the study by Ray et al. provides insight into the risk of AKI associated with vancomycin treatment. All drugs are associated with risks, and clinicians must be aware of not only the risk–benefit in specific patient cases, but also of factors that might alter the risk–benefit over time. Recent efforts to develop a standardized phenotype for drug-induced kidney disease will facilitate earlier recognition and improved risk–benefit assessment in the future (3). Clinicians are urged to carefully dose and proactively monitor vancomycin therapy, particularly in our most vulnerable patients at greatest risk for developing AKI, including the very young and old, critically ill, those with underlying CKD, and patients receiving multiple nephrotoxic medications.

Disclosures

None.

Footnotes

  • Published online ahead of print. Publication date available at www.cjasn.org.

  • See related article, “Vancomycin and the Risk of AKI: A Systematic Review and Meta-Analysis,” on pages 2132–2140.

  • Copyright © 2016 by the American Society of Nephrology

References

  1. ↵
    1. Hug BL,
    2. Keohane C,
    3. Seger DL,
    4. Yoon C,
    5. Bates DW
    : The costs of adverse drug events in community hospitals. Jt Comm J Qual Patient Saf 38: 120–126, 2012
    OpenUrlPubMed
  2. ↵
    1. Elasy TA,
    2. Anderson RJ
    : Changing demography of acute renal failure. Semin Dial 9: 438–443, 1996
    OpenUrl
  3. ↵
    1. Mehta RL,
    2. Awdishu L,
    3. Davenport A,
    4. Murray PT,
    5. Macedo E,
    6. Cerda J,
    7. Chakaravarthi R,
    8. Holden AL,
    9. Goldstein SL
    : Phenotype standardization for drug-induced kidney disease. Kidney Int 88: 226–234, 2015
    OpenUrlPubMed
  4. ↵
    1. Bates DW,
    2. Su L,
    3. Yu DT,
    4. Chertow GM,
    5. Seger DL,
    6. Gomes DR,
    7. Dasbach EJ,
    8. Platt R
    : Mortality and costs of acute renal failure associated with amphotericin B therapy. Clin Infect Dis 32: 686–693, 2001
    OpenUrlCrossRefPubMed
  5. ↵
    1. McCullough PA
    : Contrast-induced acute kidney injury. J Am Coll Cardiol 51: 1419–1428, 2008
    OpenUrlFREE Full Text
  6. ↵
    1. Levine DP
    : Vancomycin: A history. Clin Infect Dis 42[Suppl 1]: S5–S12, 2006
    OpenUrlCrossRefPubMed
  7. ↵
    1. Kirst HA,
    2. Thompson DG,
    3. Nicas TI
    : Historical yearly usage of vancomycin. Antimicrob Agents Chemother 42: 1303–1304, 1998
    OpenUrlFREE Full Text
  8. ↵
    1. Ray AS,
    2. Haikal A,
    3. Hammoud KA,
    4. Yu AS
    : Vancomycin and the risk of acute kidney injury: A systematic review and meta-analysis. Clin J Am Soc Nephrol 11: 2132–2140, 2016
    OpenUrlAbstract/FREE Full Text
  9. ↵
    1. Rybak MJ,
    2. Albrecht LM,
    3. Boike SC,
    4. Chandrasekar PH
    : Nephrotoxicity of vancomycin, alone and with an aminoglycoside. J Antimicrob Chemother 25: 679–687, 1990
    OpenUrlCrossRefPubMed
  10. ↵
    1. Elyasi S,
    2. Khalili H,
    3. Dashti-Khavidaki S,
    4. Mohammadpour A
    : Vancomycin-induced nephrotoxicity: mechanism, incidence, risk factors and special populations. A literature review. Eur J Clin Pharmacol 68: 1243–1255, 2012
    OpenUrlCrossRefPubMed
  11. ↵
    1. Smith CR,
    2. Moore RD,
    3. Lietman PS
    : Studies of risk factors for aminoglycoside nephrotoxicity. Am J Kidney Dis 8: 308–313, 1986
    OpenUrlCrossRefPubMed
  12. ↵
    1. Rybak M,
    2. Lomaestro B,
    3. Rotschafer JC,
    4. Moellering R Jr.,
    5. Craig W,
    6. Billeter M,
    7. Dalovisio JR,
    8. Levine DP
    : Therapeutic monitoring of vancomycin in adult patients: A consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Am J Health Syst Pharm 66: 82–98, 2009
    OpenUrlFREE Full Text
  13. ↵
    1. Lodise TP,
    2. Patel N,
    3. Lomaestro BM,
    4. Rodvold KA,
    5. Drusano GL
    : Relationship between initial vancomycin concentration-time profile and nephrotoxicity among hospitalized patients. Clin Infect Dis 49: 507–514, 2009
    OpenUrlCrossRefPubMed
  14. ↵
    1. van Hal SJ,
    2. Paterson DL,
    3. Lodise TP
    : Systematic review and meta-analysis of vancomycin-induced nephrotoxicity associated with dosing schedules that maintain troughs between 15 and 20 milligrams per liter. Antimicrob Agents Chemother 57: 734–744, 2013
    OpenUrlAbstract/FREE Full Text
  15. ↵
    1. Hanrahan TP,
    2. Harlow G,
    3. Hutchinson J,
    4. Dulhunty JM,
    5. Lipman J,
    6. Whitehouse T,
    7. Roberts JA
    : Vancomycin-associated nephrotoxicity in the critically ill: A retrospective multivariate regression analysis*. Crit Care Med 42: 2527–2536, 2014
    OpenUrlCrossRefPubMed
  16. ↵
    1. Lodise TP,
    2. Lomaestro B,
    3. Graves J,
    4. Drusano GL
    : Larger vancomycin doses (at least four grams per day) are associated with an increased incidence of nephrotoxicity. Antimicrob Agents Chemother 52: 1330–1336, 2008
    OpenUrlAbstract/FREE Full Text
  17. ↵
    1. Burgess LD,
    2. Drew RH
    : Comparison of the incidence of vancomycin-induced nephrotoxicity in hospitalized patients with and without concomitant piperacillin-tazobactam. Pharmacotherapy 34: 670–676, 2014
    OpenUrlCrossRefPubMed
  18. ↵
    1. Hanrahan TP,
    2. Kotapati C,
    3. Roberts MJ,
    4. Rowland J,
    5. Lipman J,
    6. Roberts JA,
    7. Udy A
    : Factors associated with vancomycin nephrotoxicity in the critically ill. Anaesth Intensive Care 43: 594–599, 2015
    OpenUrlPubMed
  19. ↵
    1. Corlan AD
    : Medline Trend: Automated Yearly Statistics of PubMed Results for Any Query, 2004. Available at: http://dan.corlan.net/medline-trend.html (WebCite archive at http://www.webcitation.org/65RkD48SV). Accessed October 21, 2016
PreviousNext
Back to top

In this issue

Clinical Journal of the American Society of Nephrology: 11 (12)
Clinical Journal of the American Society of Nephrology
Vol. 11, Issue 12
December 07, 2016
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
View Selected Citations (0)
Print
Download PDF
Sign up for Alerts
Email Article
Thank you for your help in sharing the high-quality science in CJASN.
Enter multiple addresses on separate lines or separate them with commas.
Vancomycin and the Risk of AKI: Now Clearer than Mississippi Mud
(Your Name) has sent you a message from American Society of Nephrology
(Your Name) thought you would like to see the American Society of Nephrology web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Vancomycin and the Risk of AKI: Now Clearer than Mississippi Mud
Thomas D. Nolin
CJASN Dec 2016, 11 (12) 2101-2103; DOI: 10.2215/CJN.11011016

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Request Permissions
Share
Vancomycin and the Risk of AKI: Now Clearer than Mississippi Mud
Thomas D. Nolin
CJASN Dec 2016, 11 (12) 2101-2103; DOI: 10.2215/CJN.11011016
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like

Jump to section

  • Article
    • Disclosures
    • Footnotes
    • References
  • Figures & Data Supps
  • Info & Metrics
  • View PDF

More in this TOC Section

  • Optimizing Utilization of Kidneys from Hepatitis C–Positive Kidney Donors
  • Mobile Health in Dialysis: The Best Engagement Medium Is the One that’s with Patients
  • Forever Starts Now
Show more Editorials

Cited By...

  • No citing articles found.
  • Google Scholar

Similar Articles

Related Articles

  • Vancomycin and the Risk of AKI: A Systematic Review and Meta-Analysis
  • PubMed
  • Google Scholar

Keywords

  • vancomycin
  • acute renal failure
  • nephrotoxicity
  • drug nephrotoxicity
  • acute kidney injury
  • Mississippi
  • Risk

Articles

  • Current Issue
  • Early Access
  • Subject Collections
  • Article Archive
  • ASN Meeting Abstracts

Information for Authors

  • Submit a Manuscript
  • Trainee of the Year
  • Author Resources
  • ASN Journal Policies
  • Reuse/Reprint Policy

About

  • CJASN
  • ASN
  • ASN Journals
  • ASN Kidney News

Journal Information

  • About CJASN
  • CJASN Email Alerts
  • CJASN Key Impact Information
  • CJASN Podcasts
  • CJASN RSS Feeds
  • Editorial Board

More Information

  • Advertise
  • ASN Podcasts
  • ASN Publications
  • Become an ASN Member
  • Feedback
  • Follow on Twitter
  • Password/Email Address Changes
  • Subscribe

© 2021 American Society of Nephrology

Print ISSN - 1555-9041 Online ISSN - 1555-905X

Powered by HighWire